Sensorion CEO Nawal Ouzren steps down for personal reasons

Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on hearing loss therapies, announced that Chief Executive Officer Nawal Ouzren is stepping down from her role due to personal reasons incompatible with serving as CEO.

Amit Munshi, who serves as Chairman of Sensorion, will assume the role of Interim Chief Executive Officer effective immediately. Ouzren will remain temporarily as a consultant to facilitate the transition. The Board has commenced its search for a permanent CEO.

"Since taking on the role of Chief Executive Officer back in 2017, it's been an absolute pleasure to work with the entire Sensorion team," Ouzren stated. She noted that her departure comes as the company recently completed a financing milestone anchored by Sanofi.

Munshi commented: "On behalf of the Board, I wish to thank Nawal for her exceptional leadership during her tenure as Chief Executive Officer."

The company recently announced a €60 million placement led by Sanofi with participation from healthcare institutional investors. The proceeds will advance the company's gene therapy pipeline and provide cash runway through the end of the first half of 2027.

Sensorion is developing SENS-601 (GJB2-GT) targeting hearing loss associated with GJB2 mutations, which account for approximately 50% of autosomal recessive non-syndromic congenital hearing loss. The company plans to submit SENS-601's clinical trial application in the first quarter of 2026.

The company also expects cohort two 6-month follow-up data from the Phase 1/2 Audiogene trial for SENS-501 in the first quarter of 2026.

You May Also Be Interested In

• SCI Engineered Materials CFO resigns after four months in role
• Rimini Street names new COO and CDO to expand leadership team
• Grit Metals names Jake Clark as CEO, Jeremy Poirier as chairman